Transplant Medicine is the medical discipline concerned with replacing failing or irreversibly damaged organs or tissues with functioning biological material from another source. It encompasses evaluation of potential recipients and donors, organ allocation, transplantation procedures, immunological management, infection prevention, rejection surveillance, long-term follow-up and management of transplant-specific complications. Common solid-organ transplants include kidney, liver, heart, lung and pancreas transplantation, while tissue transplantation includes structures such as corneas and certain cellular or tissue products.
Transplantation can involve living donors or deceased donors depending on the organ and circumstances. The field integrates surgery, immunology, nephrology, hepatology, cardiology, respiratory medicine, infectious diseases, pathology, pharmacology and intensive care. Its central biological challenge is that the recipient's immune system can recognise transplanted tissue as non-self and mount responses capable of damaging or destroying the graft.
Organ transplantation depends on careful donor and recipient assessment. Potential recipients are evaluated to establish the severity and reversibility of organ failure, determine whether transplantation is medically appropriate and identify factors that could increase procedural or long-term risk. Donor evaluation assesses organ function, transmissible infections, malignancy risks and other factors relevant to recipient safety. Blood-group compatibility may be important, while human leukocyte antigen characteristics and antibody profiles can influence immunological risk for particular organs.
Allocation systems differ by organ and jurisdiction and seek to distribute scarce organs according to defined clinical and ethical criteria. Waiting-list status does not simply represent chronological order because urgency, compatibility, expected benefit and other factors can influence allocation. Transplant Medicine therefore involves both individual clinical assessment and system-level management of scarce biological resources.
Rejection is an immune response against transplanted tissue and can occur through different mechanisms and at different times. Hyperacute rejection can occur rapidly when pre-existing antibodies recognise donor antigens, while acute rejection can arise through cellular or antibody-mediated immune mechanisms. Chronic rejection involves progressive changes that can impair long-term graft function. Immunosuppressive treatment reduces immune activity to protect the graft and commonly involves combinations of drugs acting through different molecular pathways.
Immunosuppression must be balanced carefully because excessive suppression increases susceptibility to infection and malignancy, while inadequate suppression increases rejection risk. Monitoring can involve organ function tests, drug concentrations, antibody assessment, imaging and, for some organs, biopsy. Rejection is therefore not simply an inevitable event after transplantation but a clinical process requiring prevention, detection and targeted management.
Immunosuppressive medicines have transformed transplantation but introduce significant long-term considerations. Calcineurin inhibitors, antimetabolites, corticosteroids and mammalian target of rapamycin pathway inhibitors are among the classes used in various transplant regimens. Their effects can include kidney toxicity, metabolic disturbances, hypertension, increased infection susceptibility and altered cancer risk, depending on the drug and patient. Drug interactions are particularly important because transplant recipients may take multiple medicines, and some anti-infective drugs can substantially change immunosuppressant concentrations. Therapeutic drug monitoring is used for selected medicines with narrow therapeutic windows. The precise regimen varies according to the transplanted organ, time since transplantation, rejection history, adverse effects and centre-specific practice. Long-term transplant care therefore requires continual adjustment rather than a fixed lifelong prescription.
Infection is a major consideration because immunosuppression reduces immune defences. Transplant recipients can develop common community infections as well as opportunistic infections that are uncommon or severe in immunocompetent individuals. Risk varies with the intensity and duration of immunosuppression, previous exposure, donor-derived infections and the type of organ transplanted. Prevention can include vaccination before transplantation when appropriate, antimicrobial prophylaxis in selected circumstances, screening and monitoring. Vaccination responses may be reduced after transplantation, and some live vaccines may be unsuitable during substantial immunosuppression. Careful assessment of fever, respiratory symptoms, gastrointestinal symptoms and abnormal laboratory findings is important because infection and rejection can sometimes produce overlapping clinical manifestations.
Living-donor transplantation allows an organ or organ segment to be obtained from a living individual under carefully regulated circumstances. Kidney donation is a major example because a healthy person can generally live with one functioning kidney, while living donation of part of the liver is possible because liver tissue can regenerate substantially. Living donation can reduce dependence on deceased-donor availability but requires assessment of donor health, voluntariness and informed consent.
The donor undergoes an operation despite receiving no direct medical benefit from the procedure, so donor safety is a central ethical and clinical requirement. Deceased-donor transplantation involves retrieval of organs from donors who have died under circumstances meeting applicable legal and medical criteria. Both pathways require rigorous consent, allocation and organ-quality processes.
Transplanted organs can provide major restoration of physiological function, but transplantation is not equivalent to a permanent cure for every underlying disease. Recipients generally require lifelong medical follow-up, and many require long-term immunosuppression. Graft function can deteriorate because of rejection, recurrent disease, chronic injury, infection, medication toxicity or other causes. Kidney transplantation, for example, can restore renal replacement function but does not eliminate every condition that contributed to kidney failure. Liver transplantation can replace severely diseased liver tissue but may involve complex management of vascular, biliary and immunological complications. Long-term outcomes depend on graft quality, recipient health, adherence, immunological factors and access to specialised follow-up.
Transplant Medicine has major ethical and social dimensions because suitable organs are limited and demand exceeds supply in many settings. Ethical frameworks commonly emphasise principles such as fairness, transparency, clinical relevance and respect for consent. Organ allocation must distinguish medically relevant criteria from factors that could introduce inappropriate discrimination. Living donation requires special safeguards because the donor accepts medical risk for another person's benefit.
Transplantation also raises questions concerning informed consent, organ procurement, privacy, cultural perspectives and equitable access to specialist care. Scientific advances in preservation, immunosuppression, desensitisation and tolerance research continue to expand possibilities, but biological and logistical constraints remain. The field therefore combines highly specialised medicine with rigorous ethical and organisational systems for managing scarce organs and lifelong recipient care.
